Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...